作者
Michael C Burger, Marie-Therese Forster, Annette Romanski, Florian Straßheimer, Jadranka Macas, Pia S Zeiner, Eike Steidl, Stefanie Herkt, Katharina J Weber, Jonathan Schupp, Jennifer H Lun, Maja I Strecker, Karolin Wlotzka, Pinar Cakmak, Corinna Opitz, Rosemol George, Iris C Mildenberger, Paulina Nowakowska, Congcong Zhang, Jasmin Röder, Elvira Müller, Kristina Ihrig, Karl-Josef Langen, Michael A Rieger, Eva Herrmann, Halvard Bonig, Patrick N Harter, Yvonne Reiss, Elke Hattingen, Franz Rödel, Karl H Plate, Torsten Tonn, Christian Senft, Joachim P Steinbach, Winfried S Wels
发表日期
2023/11/1
期刊
Neuro-oncology
卷号
25
期号
11
页码范围
2058-2071
出版商
Oxford University Press
简介
Background
Glioblastoma (GB) is incurable at present without established treatment options for recurrent disease. In this phase I first-in-human clinical trial we investigated safety and feasibility of adoptive transfer of clonal chimeric antigen receptor (CAR)-NK cells (NK-92/5.28.z) targeting HER2, which is expressed at elevated levels by a subset of glioblastomas.
Methods
Nine patients with recurrent HER2-positive GB were treated with single doses of 1 × 107, 3 × 107, or 1 × 108 irradiated CAR-NK cells injected into the margins of the surgical cavity during relapse surgery. Imaging at baseline and follow-up, peripheral blood lymphocyte phenotyping and analyses of the immune architecture by multiplex immunohistochemistry and spatial digital profiling were performed.
Results
There were no dose-limiting toxicities, and none of the patients developed a …
学术搜索中的文章
MC Burger, MT Forster, A Romanski, F Straßheimer… - Neuro-oncology, 2023